LakePharma is pleased to organize its annual Symposium to bring together individuals and organizations in the biotech community to discuss the latest developments in biologics.
The 2019 symposium will cover topics such as the latest advances in cell and gene therapies. The conference is designed to benefit scientists currently working in the biopharmaceutical industry who want to improve their awareness of the latest advancements in next-generation therapeutics, as well as non-scientists who seek a better understanding of the processes, challenges, and opportunities in the industry.
In addition to formal presentations, the symposium will include special topic workshops, a poster session, and a happy hour for networking.
Hua Tu, Ph.D. CEO, LakePharma, Inc.
Norman Garceau, Ph.D. VP, Technical Operations, LakePharma, Inc.
Brian Zabel, Ph.D. Senior Director, Discovery Immunology, LakePharma, Inc.
Alan Ashworth, Ph.D., FRS
President of Helen Diller Family Comprehensive Cancer Center at UCSF
Michael Boychyn, Ph.D.
Vice President of Process
Development at REGENXBIO Inc.
Dean Felsher, MD, Ph.D.
Director of Oncology Research,
Director of Translational Research
and Applied Medicine at Stanford
Everett Meyer, MD, Ph.D.
Medical and Scientific Director,
Cellular Therapy Facility
at Stanford University
Madhusudan Peshwa, Ph.D.
Chief Technology Officer of Global Cell
Therapy at GE Healthcare
David Schaffer, Ph.D.
Co- Founder & CSO of 4D Molecular
Therapeutics, Director of the Berkeley
Stem Cell Center at UC Berkeley
Hua Tu, Ph.D.
President and CEO of LakePharma
Pam Contag Ph.D.
8:30 am - 5:30 pm, Thursday October 10, 2019
Four parallel lunch workshops - more information coming soon.
Directed Evolution of Novel Adeno-Associated Viral Vectors for Clinical Gene Therapy, David Schaffer, Ph.D., 4D Molecular Therapeutics
A Platform for Identifying Strategies for Reversing Cancer and Restoring the Immune Response, Dean Felsher, MD, Ph.D., Stanford University
Comparison of Baculovirus (BV)-Sf9 and HEK293 Expression Systems for the Production of Adeno-Associated Virus (AAV) Vectors, Michael Boychyn, Ph.D., REGENXBIO
More sessions will be announced soon.
Please contact email@example.com for more information.
Attendee registration opening is now open. Register >>